Table 4. Management‐strategy recommendations for osimertinib‐induced dAEs.

Abbreviations: bid, twice daily; dAEs, dermatologic adverse events; EGFR, epidermal growth factor receptor; qd, every day; qid, four times daily; TKI, tyrosine kinase inhibitor.

Based on published recommendations: Lacouture et al. 2011 [8]; Califano et al. 2015 [9]; Melosky et al. 2015 [27]; Melosky, Hirsh 2014 [29]; Wu et al. 2011 [24], Chanaprapaph et al. 2014 [25]; Chu et al. 2017 [47].